[Decrease in the -SH groups of crystalline bovine albumin after thermal denaturation].

F DI JESO

Home/Archive/PubMed

PubMed · 13816420

[Decrease in the -SH groups of crystalline bovine albumin after thermal denaturation].

F DI JESO

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Albumins Animals Cattle Hematologic Tests Serum Albumin SERUM ALBUMIN/chemistry Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

F DI JESO. 1959-12-31. [Decrease in the -SH groups of crystalline bovine albumin after thermal denaturation].. https://pubmed.ncbi.nlm.nih.gov/13816420/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Hepatorenal syndrome.

Hepatorenal syndrome (HRS) is a major complication of patients with cirrhosis, with the annual incidence in patients with ascites being approximately 8% []. This syndrome develops in the latest phase of the disease and there is now evidence that it is an important determinant of patient survival. Many aspects of HRS are, however, still poorly understood. There are two types of HRS: type 1 or progressive HRS which is associated with a very poor prognosis (median survival rate lower than 2 weeks), and type 2 HRS which is characterized by a steady impairment in circulatory and renal function. The pathogenesis of HRS is a deterioration in effective arterial blood volume due to splanchnic arterial vasodilation and a reduction in venous return and cardiac output. It is therefore not surprising that the syndrome can be reversed by the simultaneous intravenous administration of albumin and arterial vasoconstrictors. Intrarenal mechanisms are also important and require prolonged improvement in circulatory function to be deactivated. Long-term administration of intravenous albumin and vasoconstrictors or the correction of portal hypertension with a transjugular intrahepatic portacaval shunt are effective in the treatment of HRS. They also appear to improve survival and may serve as a bridge to liver transplantation, which is the treatment of choice in these patients.

Albumins↗

PubMed2005

Corrosion behavior and surface characterization of titanium in solution containing fluoride and albumin.

The objective of this study was to demonstrate the role of albumin on the corrosion behavior of titanium in a solution containing 2.0 g/l fluoride and either 0.1 or 1.0 g/l albumin. The corrosion behavior and surface characterization of passive films on titanium immersed in such a solution were examined. In addition, the change in pH and the concentration of dissolved titanium in the solution were examined. The results showed that the corrosion of titanium in a solution containing fluoride was distinct, and that adding albumin to the solution containing fluoride suppressed corrosion. Fluorine was detected on the titanium surface immersed in the solution containing fluoride, and dissolution of the titanium was confirmed. The titanium immersed in a solution containing both fluoride and albumin had an albumin film regardless of the albumin concentration. In addition, the amount of dissolved titanium from the titanium immersed in the solution was less than when the solution contained no albumin. It was suggested that the formation of adsorbed albumin films on or in the passive film acted to not only protect the titanium from attack by the fluoride but also suppressed dissolution of the titanium-fluoride compounds.

Albumins↗

PubMed2004

Development and validation of a method for the purity determination of (3beta,20R)-4,4-dimethylcholesta-8,14,24-trien-3-ol(FF-MAS) in pharmaceutical products containing recombinant human albumin.

A simple and sensitive method has been developed and validated for purity determination of FF-MAS (also known as (3beta,20R)-4,4-dimethylcholesta-8,14,24-trien-3-ol an endogenous substance usually present in the pre-ovulatory follicular fluid) at very low concentrations (200 ng per unit) in pharmaceutical formulations containing RECOMBUMIN (recombinant human albumin) as the matrix. The paper focuses on development of the sample preparation for the product containing recombinant human albumin. After removal of recombinant human albumin by precipitation using a mixture of water and ethanol, the FF-MAS was concentrated by evaporation using a vacuum centrifuge and the prepared sample was analyzed. The purity method was based on a reversed-phase high performance liquid chromatography (RP-HPLC) with ultraviolet absorption detection at 250 nm. The method was validated according to ICH guidelines. The method indicated a significant degree of specificity with good selectivity and no significant effect from the matrix. The limit of detection was found to be 0.3-0.8% (depending on the impurity) corresponding to 1.9-5.1 ng. The limit of quantification was found to be 0.8-2.5% (depending on the impurity) corresponding to 5.2-16 ng. The recovery was found to be between 90 and 101% for the FF-MAS, and 100-129% for the six known impurities. The tested range for FF-MAS was from 320 to 960 ng corresponding to 50-150% of the nominal concentration (640 ng, injection volume is 100 microl). The linearity of each compound (FF-MAS and the six impurities) was investigated. The squared correlation coefficient (r(2)) was 0.999 for FF-MAS (50-150% level) and 0.977-0.998 for the six known impurities (at four levels: 0.20, 0.50, 1.00, 2.00%). The R.S.D. in the repeatability study was found to be 9.2% for the total amount of impurities, and 10.4% for single impurities. The R.S.D. in the intermediate precision study was found to be 10.9% for total impurities, and 12.0% for single impurities. The validation results showed that the method was suitable for the purity analysis. The validated method was then ready for use for samples analysis of phase II clinical studies and the stability investigations of the pharmaceutical product.

Albumins↗